

Article

Discovery of a New Chalcone-Trimethoxycinnamide Hybrid with Antimitotic Effect: Design, Synthesis, and Structure—Activity Relationship Studies

Joana Moreira ^{1,2,†}, Patrícia M. A. Silva ^{3,4,†}, Matilde Barros ⁵, Lucília Saraiva ⁵, Madalena Pinto ^{1,2}, Hassan Bousbaa ^{3,*} and Honorina Cidade ^{1,2,*}

- ¹ Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; up201302558@edu.ff.up.pt (J.M.); madalena@ff.up.pt (M.P.)
- ² Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Edifício do Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal
- ³ UNIPRO—Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal; patricia.silva@cespu.pt
- ⁴ TOXRUN—Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal
- ⁵ LAQV/REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; up201604459@edu.ff.up.pt (M.B.); lucilia.saraiva@ff.up.pt (L.S.)
- * Correspondence: hassan.bousbaa@iucs.cespu.pt (H.B.); hcidade@ff.up.pt (H.C.); Tel.: +351-224157186 (H.B.); +351-220428688 (H.C.)
- † These authors contributed equally to this work.



Citation: Moreira, J.; Silva, P.M.A.; Barros, M.; Saraiva, L.; Pinto, M.; Bousbaa, H.; Cidade, H. Discovery of a New Chalcone-Trimethoxycinnamide Hybrid with Antimitotic Effect: Design, Synthesis, and Structure—Activity Relationship Studies. *Pharmaceuticals* **2023**, *16*, 879. <https://doi.org/10.3390/ph16060879>

Academic Editor: Luis Octavio Regasini

Received: 23 April 2023

Revised: 2 June 2023

Accepted: 10 June 2023

Published: 14 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: In this work, the design and synthesis of a new chalcone-trimethoxycinnamide hybrid (**7**) based on the combination of subunits of two promising antiproliferative compounds (**CM-M345** (**1**) and **BP-M345** (**2**)), previously obtained by our research group, are reported. In order to expand the structure–activity relationship (SAR) knowledge, a new series of **7**-analogues was also designed and synthesized. All the compounds were evaluated for their antitumor activity against melanoma (A375-C5), breast adenocarcinoma (MCF-7), and colorectal carcinoma (HCT116) cell lines, as well as non-tumor HPAEpic cells. Three of the newly synthesized compounds (**6**, **7**, and **13**) exhibited potent antiproliferative activity, mainly on colorectal tumor cells ($GI_{50} = 2.66\text{--}3.26\ \mu\text{M}$), showing hybrid **7** selectivity for tumor cells. We performed molecular mechanism studies to evaluate the potential interference of compounds with the p53 pathway, namely, p53–MDM2 interaction and mitosis in HCT116 cells. The antiproliferative activities of compounds were shown to be p53-independent. Compound **7** emerged as an antimitotic agent by inducing the mitotic arrest of colorectal tumor cells, and subsequently, cell death.

Keywords: chalcones; diarylpentanoids; hybrids; antitumor activity; apoptosis; p53; mitosis

1. Introduction

Chalcones, as well as their analogues, diarylpentanoids, have gained high recognition among medicinal chemists due to their wide range of pharmacological potential [1–5]. The antitumor activities of these compounds have been recognized through their interference with several biological targets [6–9]. Our research group has reported several chalcones and diarylpentanoids with notable growth inhibitory activity in human tumor cell lines [10–15]. Particularly, chalcone **CM-M345** (**1**, Figure 1) showed potent antiproliferative activity ($2.1 \leq GI_{50} \leq 3.4\ \mu\text{M}$) in a panel of human tumor cell lines (breast adenocarcinoma MCF-7, non-small cell lung cancer NCI-H460, gastric adenocarcinoma AGS, and colorectal cancer HCT116). It also behaved as an inhibitor of the interaction between the tumor suppressor

protein p53 and its negative endogenous regulator, MDM2, in yeast-based assays [16]. More recently, the diarylpentanoid **BP-M345** (**2**, Figure 1) also displayed a potent growth inhibitory effect ($0.17 \leq \text{GI}_{50} \leq 0.45 \mu\text{M}$) on MCF-7 and NCI-H460 cells, as well as on melanoma (A375-C5), showing low cytotoxicity in non-tumor cell lines (fibroblasts, HFF-1, and pulmonary alveolar epithelial HPAEpiC cells) [12,17]. A study of the mechanisms involved in the antiproliferative effect of **BP-M345** revealed that this compound exerts its antiproliferative activity by inhibiting mitosis through microtubule perturbation and cell death induction [17]. Docking studies in the binding site of α,β -tubulin (PDB: 4O2B [18]) suggested that **BP-M345** occupies the colchicine binding site of α,β -tubulin, with one of its 3,4,5-trimethoxyphenyl groups having the same position as the trimethoxyphenyl group (A-ring) of colchicine [17]. These results were in accordance to what was expected, since the presence of a 3,4,5-trimethoxyphenyl group in some microtubule-targeting agents (MTAs), such as colchicine, combretastatin A4, and podophyllotoxin, has been considered as being important for the interaction with tubulin [19].




Figure 1. Molecular framework of designed novel hybrid derivatives.

Molecular hybridization is a useful approach in medicinal chemistry for the development of new therapeutic agents. This strategy proposes the design of a new hybrid molecule with two or more scaffolds connected in a single molecular framework to improve the pharmaceutical profile [20]. Currently, several studies have exploited hybrid molecules integrating scaffolds of diverse small molecules to be screened for a desired pharmacological activity with a good drug profile, particularly as antiproliferative agents [21].

Taking these into account, herein, we report on the design and synthesis of a novel molecular hybrid based on the combination of the subunit 3,4,5-trimethoxycinnamoyl present in **BP-M345** (**2**) and the chalcone **CM-M345** (**1**), as shown in Figure 1. An amide linker was selected as the spacer subunit, considering that cinnamides have been previously reported for their promising antitumor effect [22]. To expand knowledge of the structure–activity relationship (SAR), several analogues of the novel chalcone-trimethoxycinnamide hybrid were planned. The molecular modification strategy involved (i) replacing 3,4,5-trimethoxycinnamoyl with a 3,4,5-trimethoxyphenyl group to evaluate the impact of the

enone moiety in the antiproliferative activity (Figure 1), (ii) isosteric substitution of the amide linker with a retro-amide (Figure 1), and (iii) cyclization of the 3-carbon chain present in the chalcone scaffold to evaluate the impact of molecular rigidification (Figure 1). The potential antitumor effects of all synthesized compounds were screened in three human tumor cell lines (A375-C5, MCF-7, and HCT116), and the most promising compounds were selected, aiming to evaluate the mechanism of action related with their cytotoxicity, namely, regarding the p53–MDM2 interaction inhibition, apoptosis induction, and mitotic arrest.

2. Results


2.1. Synthesis of Chalcone-Trimethoxycinnamide Hybrid 7

The synthetic approach planned for the synthesis of chalcone-trimethoxycinnamide hybrid 7 consisted of an amidation reaction between a methylated derivative of sinapic acid and the amine derivative of chalcone **CM-M345** (**1**), as highlighted in Scheme 1A,B. The methylated derivative of sinapic acid (**4**) was obtained using a two-step synthesis involving the methylation of sinapic acid to afford methyl (*E*)-3-(3,4,5-trimethoxyphenyl)acrylate (**3**), followed by hydrolysis of the ester group to obtain 3,4,5-trimethoxycinnamic acid (**4**) (Scheme 1A). These two steps were accomplished with good yields (95% and 80%, respectively). The synthesis of the amine derivative of the chalcone **CM-M345** (**1**) was conducted in three steps (Scheme 1B). In the first step, 1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one was submitted to a nucleophilic substitution reaction with 2-(Boc-amino) ethyl bromide in the presence of K_2CO_3 and anhydrous acetone, giving rise to the acetophenone derivative *tert*-butyl (2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl)carbamate (**5**) with a good yield (90%). After that, chalcone *tert*-butyl (*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**) was synthesized via aldol condensation with 3,4,5-trimethoxybenzaldehyde, with a moderate yield (20%). The synthesis of amino chalcone was carried out through the deprotection of the BOC-protected amine through carbamate hydrolysis in acidic conditions with trifluoroacetic acid (TFA) in the presence of dichloromethane (DCM), followed by the reaction of amino chalcone with 3,4,5-trimethoxycinnamic acid (**4**) using the coupling reagent 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminoxy)-dimethylamino-morpholinomethylene)]methanaminium hexafluorophosphate (COMU) to obtain chalcone-trimethoxycinnamide hybrid 7 with 20% yield.

2.1.1. Synthesis of Compound 7 Analogues with a Chalcone Scaffold (**8** and **13**)

The chalcone-trimethoxyphenylamide hybrid, **8** (analogue of Group I), was obtained using the same synthetic approach as for **7** (Scheme 1B), except for the last step of the reaction. The amidation occurred between amino chalcone and 3,4,5-trimethoxybenzoic acid, using the coupling reagent COMU, giving rise to **8** with 20% yield.

The synthesis of another chalcone-trimethoxyphenylamide hybrid, **13** (an analogue of Group II), resulting from the isosteric substitution of the amide linker by a retro-amide, was conducted using a three-steps pathway (Scheme 1C). Firstly, methyl 2-(4-acetyl-3-hydroxy-2-propylphenoxy)acetate (**9**) was synthesized via a nucleophilic substitution reaction of 1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one with methyl bromoacetate in the presence of K_2CO_3 and anhydrous acetone as a solvent with 45% yield. The compound dimethyl 2,2'-((4-acetyl-2-propyl-1,3-phenylene)bis(oxy))diacetate (**10**) was also obtained as a by-product of the reaction in 25% yield. This reaction was followed by an aldol condensation between each synthesized acetophenone (**9** or **10**) with 3,4,5-trimethoxybenzaldehyde. In these cases, the aldol condensation reaction in basic medium also allowed for the hydrolysis of the ester group to obtain (*E*)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic acid (**11**) and (*E*)-2,2'-((2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,3-phenylene)bis(oxy))diacetic acid (**12**), respectively, with moderate yields (30% and 35%, respectively). Lastly, chalcone **11** gave rise to hybrid **13** through the reaction with 3,4,5-trimethoxyaniline in the presence of the coupling reagent COMU, with 30% yield.



Scheme 1. General procedure for the synthesis of chalcone-trimethoxycinnamide (**7**) and chalcone-trimethoxyphenylamide (**8** and **13**) hybrids. (A) Synthesis of 3,4,5-trimethoxycinnamic acid (**4**); (B) Synthesis of chalcone-trimethoxycinnamide (**7**) and chalcone-trimethoxyphenylamide (**8**) hybrids; (C) Synthesis of chalcone-trimethoxyphenylamide hybrid (**13**). Reaction conditions: (i) $(\text{CH}_3)_2\text{SO}_2$, K_2CO_3 , anhydrous acetone, 65°C ; (ii) $\text{HCl}:\text{H}_2\text{O}$, THF , 70°C ; (iii) anhydrous acetone, K_2CO_3 , 2-(Boc-amino)ethyl bromide; (iv) 3,4,5-trimethoxybenzaldehyde, NaOH , MeOH ; (v) TFA; (vi) Hünig's base, COMU, (*E*)-3-(3,4,5-trimethoxyphenyl)acrylic acid (**4**); (vii) 3,4,5-trimethoxybenzoic acid, Hünig's base, COMU; (viii) anhydrous acetone, K_2CO_3 , methyl bromoacetate; (ix) 3,4,5-trimethoxyaniline, Hünig's base, COMU.

2.1.2. Synthesis of Compound 7 Analogues with a Flavone Scaffold (**15**, **16**, and **17**)

The synthesis of compound **7** analogues with a flavone scaffold **15** and **16** (analogues of Group III) was firstly planned using chalcone **6** (previously synthesized as described in Section 2.1.1, Scheme 1B) as a building block via a two-step pathway (Method A, Scheme 2A). Firstly, flavone **14** was synthesized via the cyclization of **6** using DMSO/I_2 with a 30% yield. Subsequently, the deprotection of the BOC-protected amine of flavone **14** was accomplished using TFA, and the synthesis of flavone-trimethoxycinnamide **15** and flavone-3,4,5-trimethoxyphenylamide **16** was attempted via a coupling reaction between flavone, and 3,4,5-trimethoxycinnamic acid (**4**) or 3,4,5-trimethoxybenzoic acid, respectively. However, the expected products were not obtained. Therefore, an alternative synthetic pathway was carried out (Method B, Scheme 2B). In this strategy (Scheme 2B), hybrids **15** and **16** were obtained in a one-step synthesis from **7** and **8** hybrids, previously synthesized


as described in Section 2.1.1 (Scheme 2B). The cyclization of chalcones into corresponding flavones was carried out using DMSO/I₂ as a catalyst, giving rise to **15** and **16**, with 35 and 33% yield, respectively.

Considering that the synthesis of **15** and **16** was only accomplished via the direct cyclization of the corresponding chalcone hybrids, the flavone-3,4,5-trimethoxyphenylamide hybrid **17**, with a retro-amide as linker, was also planned using the same strategy (Method A, Scheme 2C), through the direct cyclization of **13** (previously synthesized as described in Section 2.1.1, Scheme 1C), using DMSO/I₂ as a catalyst, giving rise to **17** with a moderate yield (25%). For comparison purposes, the synthesis of **17** was also conducted in a two-step pathway (Method B, Scheme 2D), consisting of the cyclization of **11** (previously synthesized as described in Section 2.1.1, Scheme 1C) using DMSO/I₂, affording flavone **18**, which was then submitted to a reaction with 3,4,5-trimethoxyaniline in the presence of the coupling agent COMU, giving rise to **17** with a slightly lower overall yield (17.5%) when compared to Method A. The overall results allowed us to conclude that the synthesis of flavone hybrids was most favorable if the cyclization of chalcone hybrids was the last step of the synthetic pathway.

The structure elucidation of compounds **3**, **4**, and **9** was established using ¹H and ¹³C nuclear magnetic resonance (NMR) techniques (Figures S1, S2 and S7, Supplementary Materials), and data were in accordance with those previously reported [23,24]. The structural elucidation of new compounds **5–8** and **10–18** was established on the basis of NMR (Figures S3–S6 and S8–S16—Supplementary Materials) and high-resolution mass spectrometry (HRMS) (Figures S17–S29, Supplementary Materials) techniques. ¹³C NMR assignments were determined using 2D heteronuclear single quantum correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) experiments.

2.2. In Vitro Growth Inhibitory Activity of Compounds in Tumor Cell Lines

A sulforhodamine B (SRB) assay was performed to evaluate the in vitro growth inhibitory activity of all synthesized hybrids, as well as intermediates in the human tumor cell lines of melanoma (A375-C5), breast adenocarcinoma (MCF-7), and colorectal carcinoma (HCT116), as well as on the non-tumor Human Pulmonary Alveolar Epithelial cell line (HPAEpiC). The concentration inducing 50% cell growth inhibition (GI₅₀), was calculated. Among all of the tested compounds, three (**6**, **7**, and **13**) showed a high growth arrest in all cell lines, and **7** displayed potent growth inhibitory activity against the colorectal tumor HCT116 cell line (Table 1). Interestingly, the three compounds displayed a selective antiproliferative effect on the colorectal tumor cell line, with a GI₅₀ ranging from 2.66 μM to 3.26 μM. This suggested that this line may harbor intrinsic characteristics that make it more sensitive to the compounds. Notably, when comparing the GI₅₀ values in tumor cells with those in non-tumor cells (HPAEpiC), **7** showed high selectivity for tumor cells, and even higher than that obtained for two previously reported hit compounds, **CM-345** (**1**) and **BP-M345** (**2**). The overall results prompt us to further investigate the mechanism behind the cytotoxic activities of compounds **6**, **7**, and **13** in colorectal tumor cells. Moreover, in silico studies were performed, aiming to screen for drug-likeness.



Scheme 2. General procedure for the synthesis of flavone-trimethoxycinnamide (**15**) and flavone-trimethoxyphenylamide (**16** and **17**) hybrids. (A) Method A for the synthesis of flavone-trimethoxycinnamide (**15**) and flavone-trimethoxyphenylamide (**16**) hybrids. (B) Method B for the synthesis of flavone-trimethoxycinnamide (**15**) and flavone-trimethoxyphenylamide (**16**) hybrids. (C) Method A for the synthesis of flavone-trimethoxyphenylamide hybrid (**17**). (D) Method B for the synthesis of flavone-trimethoxyphenylamide hybrid (**17**). Reaction conditions: (i) I_2 (cat.), DMSO, reflux, N_2 ; (ii) TFA; (iii) 3,4,5-trimethoxycinnamic acid, Hünig's base, COMU; (v) 3,4,5-trimethoxyaniline, Hünig's base, COMU.

Table 1. Tumor cell growth inhibitory activities of compounds **1**, **2**, **6–8**, and **11–18**.

	GI ₅₀ (μM) ¹			
	A375-C5	MCF-7	HCT116	HPAEPiC
6	3.61 ± 1.11	39.81 ± 2.11	2.81 ± 0.65	9.60 ± 0.94
7	32.07 ± 1.27	>75	3.26 ± 1.39	57.17 ± 8.68
8	>75	>75	13.49 ± 2.46	>75
11	29.36 ± 1.05	58.34 ± 8.37	26.87 ± 1.60	>75
12	>75	>75	>75	>75
13	9.37 ± 0.90	18.80 ± 3.46	2.66 ± 0.87	10.83 ± 0.23
14	>75	>75	>75	>75
15	>75	>75	>75	>75
16	>75	>75	28.57 ± 5.05	>75
17	>75	>75	24.68 ± 3.04	>75
18	>75	>75	>75	>75
CM-M345 (1)	5.57 ± 0.06	2.3 ± 0.1 ²	2.6 ± 0.2 ²	6.10 ± 0.66
BP-M345 (2)	0.24 ± 0.01 ³	0.45 ± 0.06 ³	0.17 ± 0.01 ⁴	1.07 ± 0.16 ³
Doxorubicin	0.028 ± 0.002	0.083 ± 0.003	0.085 ± 0.008	0.091 ± 0.013

¹ GI₅₀ represents the concentration that causes 50% cell growth inhibition at 48 h. Doxorubicin was used as positive control. The results are expressed as mean ± standard deviation from three independent experiments; ² Hit compound previously reported by Pereira et al. [16]; ³ Hit compound previously reported by Novais et al. [17]; ⁴ Results previously reported by Moreira et al. [12].

Considering the antiproliferative effects on tumor cells of all the studied compounds (Table 1), some SAR considerations may be undertaken (Figure 2). Comparing hybrids with the same linker, for chalcone derivatives, the replacement of the 3,4,5-trimethoxycinnamoyl group (**7**) by a 3,4,5-trimethoxyphenyl group (**8**) is associated with a reduction in activity, suggesting that the α,β -unsaturated ketone moiety on the linker is an important feature in the enhancement of the antiproliferative activity (**7**: GI₅₀ = 3.26 μM vs. **8**: GI₅₀ = 13.49 μM). Nevertheless, this effect is not observed for the flavone derivatives **15** and **16**. Concerning the isosteric substitution of the amide linker by a retro-amide, for chalcone derivatives (**8** vs. **13**), the results suggested that the presence of the carbonyl of the amide group adjacent to the 3,4,5-trimethoxyphenyl ring was less favorable for the activity (**8**: GI₅₀ = 13.49 μM vs. **13**: GI₅₀ = 2.66 μM), but for flavone derivatives, this isosteric substitution has no effect on the activity. Interestingly, the cyclization of chalcones, resulting in flavone-hybrids (**15**, **16**, and **17**, GI₅₀ = 24.68–>75 μM) led to the loss of antiproliferative activity, compared with chalcone-hybrids (**7**, **8**, and **13**, GI₅₀ = 2.66–3.26 μM). Additionally, with the screening of the synthetic intermediates, some conclusions can also be inferred (Figure 2). When comparing the antiproliferative activities of chalcone derivatives **11** and **12** with **CM-M345 (1)**, it seems that the substitution of the hydroxyl group by a carboxylic acid side chain in the 4' position of the chalcone scaffold (**11**) is associated with a remarkable decrease in the growth inhibitory effect (a GI₅₀ between 26.87 and 58.34 μM), compared with the compound **CM-M345 (1)**, a GI₅₀ between 2.3 and 2.6 μM), and the substitution of both hydroxyl groups at 2' and 4' is associated with a complete loss of activity (**12**, GI₅₀ > 75 μM). However, the presence of a BOC-protected amine in the 4' position of the chalcone scaffold is tolerated (**6**, a GI₅₀ between 2.81 and 39.81 μM).




Figure 2. Putative SARs for synthesized compounds with antiproliferative activities.

2.3. Effect of Compounds 6, 7, and 13 on the p53–MDM2 Interaction

Since the antiproliferative activity of **CM-M345 (1)** was associated with a p53–MDM2 inhibitory effect, and compounds **6**, **7**, and **13** displayed a preferential antiproliferative effect on HCT116 p53^{+/+} cells, they were also tested in HCT116 cells, in which p53 has been knocked out (HCT116 p53^{-/-}), in order to confirm the contribution of the p53 pathway to the antiproliferative activity (Table 2).

Table 2. Tumor cell growth inhibitory activities of compounds **6**, **7**, and **13** in human tumor HCT116 p53^{+/+} and HCT116 p53^{-/-} cells.

	GI ₅₀ (μM) ¹		SI ²
	HCT116 p53 ^{+/+}	HCT116 p53 ^{-/-}	
6	2.81 ± 0.65	1.9 ± 0.3	0.68
7	3.26 ± 1.39	1.3 ± 0.09	0.40
13	2.66 ± 0.87	4.1 ± 0.5	1.54
CM-M345 (1) ³	2.6 ± 0.2 ²	3.4 ± 0.1 ²	1.31

¹ GI₅₀ represents the concentration that causes 50% cell growth inhibition at 48 h. ² Selective index (GI₅₀ of HCT116 p53^{-/-}/GI₅₀ of HCT116 p53^{+/+}). Etoposide was used as positive control: GI₅₀ (HCT116 p53^{+/+}) = 0.71 ± 0.09 μM. ³ Hit compound previously reported by Pereira et al. [16]. The results are expressed as mean ± standard deviation from 3–5 independent experiments.

Compounds **6**, **7**, and **13** presented similar antiproliferative activities in both cell lines, suggesting that the growth inhibitory effect of compounds was p53-independent. However, since **CM-M345 (1)** has been previously reported as a p53–MDM2 inhibitor by our research group [16], the effect of 10 μM of compounds **6**, **7**, and **13** on the p53–MDM2 interaction was analyzed using yeast cell-based assays. The results obtained showed that none of the tested compounds significantly reversed the negative inhibitory growth effect of MDM2 on p53 (data not shown).

2.4. Effects of Compounds 6, 7, and 13 on HCT116 Cellular Apoptosis

Double labeling with annexin V-FITC and propidium iodide dyes was used to detect cells going through apoptotic events, using a flow cytometer in order to obtain insights into the mechanism by which compounds **6**, **7**, and **13** generate antiproliferative activity against colorectal carcinoma cells. For that, HCT116 cells were exposed to each compound for 48 h.

As shown in Figure 3, the compounds induced apoptosis, when compared to untreated or DMSO-treated control cells. The data suggest that these compounds inhibited the growth of HCT116 tumor cells through apoptosis.




Figure 3. Treatment with 6, 7, and 13 induces apoptotic tumor cell death. (a) Representative flow cytometry histogram of propidium iodide (PI) and Annexin V (FITC-A) staining in untreated cells and tumor cells treated with 6, 7, and 13 at the indicated concentrations, for 48 h. DMSO was used as a control. The quadrants Q were defined as Q1 = live cells (Annexin V-negative/PI-negative), Q2 = early stage of apoptosis (Annexin V-positive/PI-negative), Q3 = late stage of apoptosis (Annexin V-positive/PI-positive) and Q4 = necrosis (Annexin V-negative/PI-positive). (b) Quantification of Annexin V-positive cells (early and late apoptosis) from the data shown in (a). * $p < 0.05$ and *** $p < 0.001$ via unpaired t-test from three independent experiments.

2.5. Effect of Compound 7 on HCT116 Mitotic Arrest

Disruption of cell cycle progression is considered one of the most common cytotoxic mechanisms of anticancer drugs [25]. Moreover, the antimetabolic effect of **BP-M345** (**2**) has been previously reported [17]. Therefore, compounds **6**, **7**, and **13** were tested for their capability to induce cell cycle arrest. HCT116 cells were exposed for 24 h to the compounds and then analyzed using phase contrast microscopy for morphological changes. Untreated and dimethyl sulfoxide (DMSO; solvent)-treated cells were used as negative controls. Cell exposure to nocodazole, an antimetabolic agent, was used as a positive control. We found an accumulation of bright and rounded cells, reminiscent of mitotic cells, under **7** treatment, which was not observed under **6** or **13** treatment (Figure 4a). DAPI staining of **7**-treated cells to visualize the DNA, confirmed the accumulation of mitotic cells through the observation of condensed chromosomes (Figure 4b), while untreated and DMSO-treated cells showed only a few cells in mitosis, as expected. We thus calculated the mitotic index (MI), and observed a significant increase in MI in **7**-treated cells ($22.76 \pm 4.30\%$) compared to the untreated ($12.68 \pm 1.98\%$) or DMSO-treated ($12.81 \pm 1.45\%$) (Figure 4c). Interestingly, the MI after treatment with **7**, used at GI_{50} , was of the same magnitude as the previously reported MI ($29.8 \pm 5.6\%$) induced by the parent compound **BP-M345** (**5**) used at $2 \times GI_{50}$ [17].




Figure 4. Screening of antimetabolic activities of **6**, **7**, and **13**. (a) Representative phase-contrast microscopy images of untreated HCT116 cells and cells treated with the indicated compounds for 24 h, showing accumulation of rounded and bright cells after treatment with **7**. Cells treated with DMSO and Nocodazole were used as controls. Bar, 10 μm. (b) Representative DAPI staining images of untreated and **7**-treated tumor cells for 24 h, confirming the presence of mitotic cells via DNA condensation. DMSO and Nocodazole were used as controls. Bar, 5 μm. (c) Bar graph showing the mitotic index after exposure to **7** for 24 h. ** $p < 0.01$ via unpaired t-test from three independent experiments.

These results suggest that compound 7 exerts its antiproliferative activity on colorectal tumor cells by inducing apoptotic cell death, probably by acting as an antimitotic agent.

2.6. Effect of Compound 7 on Mitotic Spindle Morphology

To understand the mechanism behind the induction of mitotic arrest after treatment with the compound 7, we treated HCT116 cells with the GI_{50} of the compound. Twenty-four hours later, we performed an immunofluorescence assay using an anti- α -tubulin antibody to visualize the spindle morphology. Under fluorescence microscopy, we observed that most compound 7-treated cells showed collapsed mitotic spindles ($91.41 \pm 4.87\%$), contrasting with untreated or DMSO-treated cells ($2.20 \pm 3.13\%$ and $2.86 \pm 2.85\%$, respectively) (Figure 5). Likewise, the percentage of bipolar spindles (the normal morphology of a mitotic spindle) found in compound 7-treated cells ($6.57 \pm 2.13\%$) was significantly lower than in untreated or DMSO-treated cells ($97.80 \pm 3.13\%$ and $96.43 \pm 2.72\%$, respectively) (Figure 5). This finding indicates that compound 7 induces mitotic delay by interfering with mitotic spindle assembly by generating monopolar-like spindles.




Figure 5. Compound 7 affects mitotic spindle morphology. (a) Representative immunofluorescence images of untreated cells (upper panel) with a normal bipolar spindle and compound 7-treated cells (lower panel) showing a collapsed spindle. Spindle microtubules (green) were stained with anti- α -tubulin antibodies, and DNA (blue) with DAPI. Bar, 5 μ m. (b) Percentage of bipolar and monopolar spindles in untreated/DMSO and compound 7-treated cells. **** $p < 0.0001$ untreated monopolar vs. compound 7-treated monopolar and untreated bipolar vs. compound 7-treated bipolar via two-way ANOVA with Tukey multiple comparison test from three independent experiments.

2.7. In Silico Prediction of Drug-Likeness of Compounds 6, 7, and 13

The most promising compounds (6, 7, and 13) were screened for drug-likeness properties using in silico models. The drug-likeness was evaluated according to the following chemical features: (i) flexibility, inferred by the number of rotatable bonds (RBs); (ii) unsaturation, inferred by the fraction of carbon sp³ (Fsp³); (iii) solubility, inferred by log S; (iv) polarity, inferred by the polar surface area (PSA); and (v) lipophilicity, inferred by the log P, using the SwissADME web server (SwissADME, <http://www.swissadme.ch/>, (accessed on 12 May 2023)). For each compound, the above-mentioned molecular descriptors/physicochemical properties were calculated (Table S1, Supporting Material). For each chemical feature, the obtained mean values were compared with the range of values preconized by the drug-likeness guidelines. Based on Table S1, the range of values of MW for compounds 6, 7, and 13 (515.60 – 635.70 g mol^{−1}) were higher than the recommended range of values according to the drug-likeness guidelines ($150 < MW < 500$), as well as the mean MW value (313 g mol^{−1}) reported for orally bioavailable cancer drugs [26].

The number of RBs and aromatic character, inferred through unsaturation (Fsp³), and the fraction of aromatic heavy atoms (Far = AHA/HA) are frequently used to infer molecular flexibility. Analyzing these molecular descriptors for all compounds, it was

observed that while the number of Fsp3 respects the values preconized by the drug-likeness guidelines, the RB value obtained did not ($0.25 < \text{Fsp3} < 1$; $0 < \text{RB} < 9$).

The molecular polarity can be determined by the number of HBA, the number of HBD, and the PSA values. Regarding these values (Table S1), it was observed that for compounds **6**, **7**, and **13**, the values of HBD and PSA were in agreement with the literature for synthetic drugs (a mean HBA of 4.8; a mean HBD of 1.6; $20 < \text{PSA} < 125 \text{ \AA}^2$) [27].

Lipophilicity and solubility were inferred by log P and Log S, respectively, using different methods (Table S1). Considering the range of values of Log P preconized by the drug-likeness guidelines ($0 < \text{Log P} < 5$) [26], all compounds respect preconized limits, showing that compounds **6**, **7**, and **13** have a higher mean Log P value ($4.61 < \text{mean Log P value} < 5.15$) than anticancer drugs ($2.35 < \text{mean Log P value} < 3.52$). Considering the range of values of Log S preconized by the drug-likeness guidelines ($\text{Log S} > -4$) [28], all compounds might face problems of solubility ($-8.35 < \text{mean Log S value} < -6.93$).

Therefore, taking into account the overall results, in the near future, the optimization of compounds **6**, **7**, and **13** should also consider the improvement of their drug-likeness profile, namely through nanotechnology [29]. In fact, this strategy has been proven to be effective for improving the oral bioavailability of anticancer drugs acting as MTAs with a low solubility, such as paclitaxel [30] and docetaxel [31], and some nanodelivery systems are now under clinical trial.

3. Materials and Methods

3.1. Chemistry

All reactions were monitored using thin-layer chromatography (TLC). The purification of compounds via flash column chromatography (CC) and preparative TLC was performed using Macherey-Nagel silica gel 60 (0.04–0.063 mm) and Macherey-Nagel silica gel 60 (GF254) plates, respectively. Melting points were obtained under a Köfler microscope and are uncorrected. ^1H and ^{13}C NMR spectra were taken in CDCl_3 , DMSO, or THF at room temperature on Bruker Avance 300 and 400 instruments (300.13 MHz or 400.13 MHz for ^1H , and 75.47 MHz or 100.63 MHz for ^{13}C). Chemical shifts are expressed in δ (ppm) values relative to tetramethylsilane (TMS), used as an internal reference; ^{13}C NMR assignments were made using 2D (HSQC and HMBC) NMR experiments (long-range ^{13}C - ^1H coupling constants were optimized to 7 Hz). The spectral treatment was executed using the MestReNova v6.0.2-5475 software. The HRMS mass spectra of compounds were performed on an LTQ Orbitrap XL hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), controlled by LTQ Tune Plus 2.5.5 and Xcalibur 2.1.0. at CEMUP—University of Porto, Portugal. Ions were generated using a Combi MALDI electrospray ionization (ESI) source. All reagents were purchased from Sigma Aldrich. The following materials were synthesized and purified using the described procedures. The HPLC system consisted of a Thermo Scientific SpectraSystem P4000 pump equipped with a degasser, a Thermo Scientific SpectraSystem AS3000 autosampler fitted with a maximum volume of a 100 μL loop, and a Thermo Scientific SpectraSystem UV8000 DAD detector (USA). Data acquisition was performed using ChromQuest 5.0 software, version 3.2.1. The column used in this study was ACE-C18 (150 \times 4.6 mm I.D., particle size 5 μm) manufactured by Advanced Chromatography Technologies Ltd. (Aberdeen, Scotland, UK). The mobile phase composition was acetonitrile and water (70:30 *v/v*, for compounds **5–10**, and **13–18**) or acetonitrile and water (50:50 *v/v*; 0.1% $\text{CH}_3\text{CO}_2\text{H}$, for compounds **11** and **12**, all were HPLC grade solvents obtained from Merck Life Science S.L.U. (Darmstadt, Germany). The flow rate was 1.0 mL/min and the UV detection wavelength was set at 254 nm. Analyses were performed at room temperature in an isocratic mode for 30 min. The peak purity index was determined using a total peak UV-Vis spectra of between 210 and 650 nm, with a step of 4 nm.

3.1.1. Synthesis of Chalcone-Trimethoxycinnamide Hybrid 7

Synthesis of Methyl (*E*)-3-(3,4,5-Trimethoxyphenyl) Acrylate (**3**) 3,4,5-Trimethoxycinnamic Acid (**4**)

Methyl (*E*)-3-(3,4,5-trimethoxyphenyl) acrylate (**3**) and 3,4,5-trimethoxycinnamic acid (**4**) were synthesized (95% and 80% yield, respectively) and characterized according to the described procedure [24]. An experimental description of compounds **3** and **4** is presented in the Supplementary Materials.

Synthesis of *tert*-Butyl (2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl)carbamate (**5**)

1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one (1 g, 1 Eq, 5 mmol) was dissolved in 15 mL of anhydrous acetone. Then, K₂CO₃ (4 g, 5 Eq, 30 mmol) and 2-(Boc-amino)-ethyl bromide (1 g, 1.2 Eq, 6 mmol) were added. The reaction proceeded for 24 h at 70 °C with gentle stirring. After cooling, the reaction mixture was poured onto ice and neutralized with HCl. The obtained solid was filtrated, washed with water, and dried. A white solid (90% yield) corresponding to *tert*-butyl (2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl)carbamate (**5**) was obtained.

***tert*-butyl (2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl)carbamate (**5**):** 99.3% purity; mp 175–177 °C (acetone); ¹H NMR (CDCl₃, 300.13 MHz) δ: 12.74 (s, 1H, 2-OH), 7.58 (d, *J* = 8.9 Hz, 1H, H-6), 6.42 (d, *J* = 8.9 Hz, 1H, H-5), 4.91 (sl, 1H, H-3''), 4.09 (t, *J* = 5.2 Hz, 2H, H-1''), 3.56 (q, *J* = 5.6 Hz, 2H, H-2''), 2.63 (t, *J* = 7.5 Hz, 1H, H-1'), 1.58–1.50 (m, 2H, H-2'), 2.56 (s, 3H, 1-COCH₃), 1.45 (s, 9H, H-6''), 0.94 (t, *J* = 7.4 Hz, 3H, H-3') ppm. ¹³C NMR (CDCl₃, 75.47 MHz) δ: 203.2 (1-COCH₃), 162.5 (C-4), 162.3 (C-2), 156.0 (C-4''), 130.2 (C-6), 118.5 (C-3), 114.6 (C-1), 102.9 (C-5), 79.8 (C-5''), 67.6 (C-1''), 40.2 (C-2''), 28.5 (C-6''), 26.5 (1-COCH₃), 24.5 (C-1'), 22.1 (C-2'), 14.3 (C-3') ppm; HRMS (ESI⁺): *m/z* Anal. Calc. for C₁₈H₂₇NO₅ (M+Na⁺) 360.17814., found 360.17821.

Synthesis of *tert*-Butyl (*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**)

To a solution of *tert*-butyl (2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl)carbamate (**5**, 200 mg, 1 Eq, 593 μmol) in methanol was added an aqueous solution of sodium hydroxide (40%) to pH 13–14. Then, a solution of 3,4,5-trimethoxybenzaldehyde (349 mg, 3 Eq, 1.78 mmol) in methanol was slowly added to the reaction mixture. The reaction was refluxed for 4 days. After cooling, the reaction was poured onto crushed ice, and the pH was adjusted to 6–8 with a 5 M HCl solution. The obtained solid was filtrated, washed with water, and purified via flash CC (SiO₂; hexane:ethyl acetate, 7:3). A yellow solid (20% yield) corresponding to *tert*-butyl(*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**) was obtained.

***tert*-butyl(*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**):** 98.9% purity; mp 196–198 °C (ethyl acetate); ¹H NMR (DMSO, 400.13 MHz) δ: 13.68 (s, 1H, 2-OH), 8.27 (d, *J* = 9.2 Hz, 1H, H-6), 7.98 (d, *J* = 15.4 Hz, 1H, H-β), 7.79 (d, *J* = 15.4 Hz, 1H, H-α), 7.26 (s, 2H, H-2''', -6'''), 7.00 (t, *J* = 5.7 Hz, 1H, H-3'''), 6.69 (d, *J* = 9.2 Hz, 1H, H-5), 4.10 (t, *J* = 5.6 Hz, 2H, H-1''), 3.87 (s, 6H, 3'''-, 5'''-OCH₃), 3.72 (s, 3H, 4'''-OCH₃), 3.35 (t, *J* = 5.6 Hz, 2H, H-2''), 2.59 (t, *J* = 7.5 Hz, 1H, H-1'), 1.52–1.45 (m, 2H, H-2'), 1.39 (s, 9H, H-6''), 0.89 (t, *J* = 7.3 Hz, 3H, H-3''') ppm; ¹³C NMR (DMSO, 100.63 MHz) δ: 192.4 (C=O), 162.7 (C-2), 162.6 (C-4), 155.7 (C-4''), 153.1 (C-3''', -5'''), 144.7 (C-β), 140.0 (C-4'''), 130.6 (C-6), 130.1 (C-1'''), 120.2 (C-α), 117.1 (C-3), 113.9 (C-1), 106.9 (C-2''', -6'''), 103.3 (C-5), 77.7 (C-5''), 67.0 (C-1''), 60.2 (4'''-OCH₃), 56.2 (3'''-, 5'''-OCH₃), 40.0 (C-2''), 28.2 (C-6''), 24.3 (C-1'), 21.9 (C-2'), 14.0 (C-3') ppm; HRMS (ESI⁺): *m/z* Anal. Calc. for C₂₈H₃₇NO₈ (M+Na⁺) 538.24114., found 538.24191.

Synthesis of (*E*)-*N*-(2-(3-Hydroxy-2-propyl-4-((*E*)-3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (**7**)

Tert-butyl(*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**, 150 mg, 1 Eq, 291 μmol) was dissolved in 5 mL of dichloromethane, and

then 5 mL of TFA was added to the mixture. The reaction proceeded for 26 h with gentle stirring. After completion, the reaction mixture was diluted with dichloromethane, and then a saturated sodium hydrogen carbonate solution was added. The solution was then extracted with ethyl acetate (3 × 50 mL). The organic layers were collected, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude obtained was reserved. Then, in a round-bottomed flask, (*E*)-3-(3,4,5-trimethoxyphenyl)acrylic acid (80 mg, 1 Eq, 0.34 mmol) was dissolved in 5 mL of anhydrous dichloromethane and *N*-ethyl-*N*-isopropylpropan-2-amine (87 mg, 0.12 mL, 2 Eq, 0.67 mmol) was added. Then, 50% of the crude material was added to the mixture. After 10 min, COMU (0.22 g, 1.5 Eq, 0.50 mmol) was also added to the mixture. The reaction proceeded for 20 h at room temperature with stirring. After completion, the reaction mixture was poured into ice. The solution was subsequently washed with dichloromethane (3 × 80 mL), with a 1 M HCl solution and saturated NaHCO₃ solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and solvent evaporated under reduced pressure. The reaction mixture obtained was dissolved in chloroform and purified using TLC (SiO₂; chloroform:methanol, 95:5). A yellow solid (20% yield) corresponding to (*E*)-*N*-(2-(3-hydroxy-2-propyl-4-((*E*)-3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (**7**) was obtained.

(*E*)-*N*-(2-(3-hydroxy-2-propyl-4-((*E*)-3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (**7**): 98.9% purity; mp 205–207 °C (chloroform); ¹H NMR (CDCl₃, 300.13 MHz) δ: 13.68 (s, 1H, 2-OH), 8.32–8.27 (m, 1H, 3''-NH-, H-6), 7.99 (d, *J* = 15.4 Hz, 1H, H-β), 7.79 (d, *J* = 15.3 Hz, 1H, H-α), 7.28 (s, 2H, H-2''', -6'''), 6.89 (s, 2H, H-6'', -10''), 6.87 (d, *J* = 15.8 Hz, 1H, H-β'), 6.62 (d, *J* = 15.8 Hz, 1H, H-α'), 6.73 (d, *J* = 9.2 Hz, 1H, H-5), 4.21 (t, *J* = 5.5 Hz, 2H, H-1''), 3.87 (s, 6H, 3'''-, 5'''-OCH₃), 3.80 (s, 6H, 7'''-, 9'''-OCH₃), 3.72 (s, 3H, 4'''-OCH₃), 3.78 (sl, 2H, H-2''), 3.67 (s, 3H, 8'''-OCH₃), 2.60 (t, *J* = 7.5 Hz, 1H, H-1'), 1.54–1.44 (m, 2H, H-2'), 0.88 (t, *J* = 7.4 Hz, 3H, H-3'') ppm; ¹³C NMR (CDCl₃, 75.47 MHz) δ: 192.5 (C=O), 165.4 (C-4''), 162.7 (C-2), 162.6 (C-4), 153.2 (C-3''', -5'''), 153.1 (C-7'', -9''), 144.8 (C-β), 140.0 (C-4'''), 139.1 (C-4''), 130.5 (C-6), 130.5 (C-1'''), 130.1 (C-5''), 121.3 (C-α'), 120.4 (C-α), 117.2 (C-3), 114.0 (C-1), 106.9 (C-2''', -6'''), 104.9 (C-6'', -10''), 103.6 (C-β'), 103.4 (C-5), 66.9 (C-1''), 60.2 (4'''-OCH₃), 60.1 (8'''-OCH₃), 56.2 (3'''-, 5'''-OCH₃), 56.0 (7'''-, 9'''-OCH₃), 38.7 (C-2''), 24.0 (C-1'), 21.6 (C-2'), 14.1 (C-3') ppm; HRMS (ESI⁺): *m/z* Anal. Calc. for C₃₅H₄₁NO₁₀ (M+Na⁺) 658.26227., found 658.26343.

3.1.2. Synthesis of Compound **7** Analogues with a Chalcone Scaffold (**8** and **13**)

Synthesis of (*E*)-*N*-(2-(3-Hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3,4,5-trimethoxybenzamide (**8**)

Tert-butyl(*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (**6**, 150 mg, 1 Eq, 291 μmol) was dissolved in 5 mL of dichloromethane. Then, 5 mL of TFA was added to the mixture. The reaction proceeded for 26 h with gentle stirring. After completion, the reaction mixture was diluted with dichloromethane, and then a saturated sodium hydrogen carbonate solution was added. The solution was then extracted with ethyl acetate (3 × 50 mL). The organic layers were collected, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude obtained was reserved. Then, in a round-bottomed flask, 3,4,5-trimethoxybenzoic acid (85 mg, 1 Eq, 0.40 mmol) was dissolved in 5 mL of anhydrous dichloromethane and *N*-ethyl-*N*-isopropylpropan-2-amine (0.10 g, 0.14 mL, 2 Eq, 0.80 mmol) was added. Then, 50% of the crude material was added to the mixture. After 10 min, COMU (0.26 g, 1.5 Eq, 0.60 mmol) was also added to the mixture. The reaction proceeded for 3 h at room temperature with stirring. After completion, the reaction mixture was poured onto ice. The solution was subsequently washed with 1M HCl solution and saturated NaHCO₃ solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and solvent evaporated under reduced pressure. The reaction mixture obtained was purified via TLC (SiO₂; dichloromethane:methanol; 97:3). A light-yellow solid (20% yield) correspond-

ing to (*E*)-*N*-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3,4,5-trimethoxybenzamide (**8**) was obtained.

(*E*)-*N*-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3,4,5-trimethoxybenzamide (8**):** 97.8% purity; mp 201–203 °C (chloroform); ¹H NMR (DMSO, 400.13 MHz) δ: 13.67 (s, 1H, 2-OH), 8.63 (t, *J* = 5.5 Hz, 1H, 3''-NH-), 8.28 (d, *J* = 9.1 Hz, 1H, H-6), 7.98 (d, *J* = 15.4 Hz, 1H, H-β), 7.29 (d, *J* = 15.3 Hz, 1H, H-α), 7.26 (s, 2H, H-2''', -6'''), 7.20 (s, 2H, H-6'', -10''), 6.76 (d, *J* = 9.0 Hz, 1H, H-5), 4.28 (t, *J* = 5.6 Hz, 2H, H-1''), 3.87 (s, 6H, 3'''-, 5'''-OCH₃), 3.82 (s, 6H, 7''-, 9''-OCH₃), 3.72 (s, 3H, 4'''-OCH₃), 3.69–3.66 (m, 2H, H-2''), 3.68 (s, 3H, 8''-OCH₃), 2.58 (t, *J* = 7.3 Hz, 1H, H-1'), 1.49–1.40 (m, 2H, H-2'), 0.82 (t, *J* = 7.3 Hz, 3H, H-3') ppm; ¹³C NMR (DMSO, 100.63) δ: 192.4 (C=O), 166.0 (C-4''), 162.7 (C-2), 162.6 (C-4), 153.1 (C-3''', -5'''), 152.5 (C-7'', -9''), 144.7 (C-β), 140.0 (C-4'''), 140.0 (C-4''), 130.6 (C-6), 130.6 (C-1'''), 129.5 (C-5''), 120.2 (C-α), 117.1 (C-3), 113.9 (C-1), 106.9 (C-2''', -6'''), 104.8 (C-6'', -10''), 103.4 (C-5), 66.5 (C-1''), 60.2 (4'''-OCH₃), 60.1 (8''-OCH₃), 56.2 (3'''-, 5'''-OCH₃), 56.0 (7''-, 9''-OCH₃), 38.9 (C-2''), 23.9 (C-1'), 21.0 (C-2'), 14.0 (C-3') ppm; HRMS (ESI⁺): *m/z* Anal. Calc. for C₃₃H₃₉NO₁₀ (M+Na⁺) 632.24662, found 632.24594.

Synthesis of Methyl 2-(4-Acetyl-3-hydroxy-2-propylphenoxy)acetate (**9**) and Dimethyl 2,2'-((4-acetyl-2-propyl-1,3-phenylene)bis(oxy))diacetate (**10**)

1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one (1 g, 1 Eq, 5.149 mmol) was dissolved in 5 mL of anhydrous acetone. Then, K₂CO₃ (711.5 mg, 1 Eq, 5.149 mmol) and methyl 2-bromoacetate (945.1 mg, 584.9 μL, 1.2 Eq, 6.178 mmol) were added. The reaction proceeded for 24 h at 70 °C with gentle stirring. After cooling, the reaction mixture was poured onto ice and neutralized with HCl. The obtained solid was filtrated, washed with water, and dried. A white solid (45% yield) corresponding to methyl 2-(4-acetyl-3-hydroxy-2-propylphenoxy)acetate (**9**) was obtained. The aqueous phase was then extracted with dichloromethane (3 × 50 mL). The organic layers were collected, washed with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified using flash CC (SiO₂; n-hexane:ethyl acetate, 7:3). A gum (25% yield) corresponding to dimethyl 2,2'-((4-acetyl-2-propyl-1,3-phenylene)bis(oxy))diacetate (**10**) was obtained.

The experimental description of compound **9** is presented in the Supplementary Materials.

Dimethyl 2,2'-((4-acetyl-2-propyl-1,3-phenylene)bis(oxy))diacetate (10**):** 99.7% purity; mp N.D. (gum); ¹H NMR (CDCl₃, 300.13 MHz) δ: 7.50 (d, *J* = 8.7 Hz, 1H, H-6), 6.53 (d, *J* = 8.7 Hz, 1H, H-5), 4.69 (s, 2H, H-1''), 4.47 (s, 2H, H-1'''), 3.81 (s, 3H, H-3''), 3.79 (s, 3H, H-3'''), 2.69 (t, *J* = 7.8 Hz, 2H, H-1'), 1.63–1.53 (m, 2H, H-2'), 2.56 (s, 3H, 1-COCH₃), 0.97 (t, *J* = 7.4 Hz, 3H, H-3') ppm; ¹³C NMR (CDCl₃, 75.47 MHz) δ: 198.9 (1-COCH₃), 169.2 (C-2'''), 168.9 (C-2''), 160.1 (C-4), 156.8 (C-2), 129.2 (C-6), 126.8 (C-1), 126.4 (C-3), 107.1 (C-5), 71.8 (C-1'''), 65.3 (C-1''), 52.4 (C-3'''), 52.2 (C-3''), 30.0 (1-COCH₃), 26.0 (C-1'), 22.9 (C-2'), 14.5 (C-3') ppm; HRMS (ESI⁺): *m/z* Anal. Calc. for C₁₇H₂₂O₇ (M+Na⁺) 361.12577, found 361.12594.

Synthesis of (*E*)-2-(3-Hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic Acid (**11**)

To a solution of methyl 2-(4-acetyl-3-hydroxy-2-propylphenoxy)acetate (**9**, 200 mg, 1 Eq, 751 μmol) in methanol was added an aqueous solution of 40% sodium hydroxide to pH 13–14. Then, a solution of 3,4,5-trimethoxybenzaldehyde (442 mg, 3 Eq, 2.25 mmol) in methanol was slowly added to the reaction mixture. The reaction was refluxed for 2 days. After cooling, the reaction was poured into crushed ice and neutralized with a 5 M HCl solution. The solution was then extracted with ethyl acetate (3 × 50 mL). The organic layers were collected, washed with water, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the obtained reaction mixture was purified via flash CC (SiO₂; chloroform:methanol, 95:5). A yellow solid (30% yield) corresponding to (*E*)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic acid (**11**) was obtained.

(E)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic acid (11): 98.7% purity; mp 200–202 °C (chloroform); ¹H NMR (DMSO, 400.13 MHz) δ: 13.39 (s, 1H, 2-OH), 12.73 (s, 1H, 2''-OH), 7.79 (d, J = 15.6 Hz, 1H, H-β), 7.75 (d, J = 9.2 Hz, 1H, H-6), 7.56 (d, J = 8.8 Hz, 1H, H-5), 7.45 (d, J = 15.4 Hz, 1H, H-α), 6.86 (s, 2H, H-2''', -6'''), 4.72 (sl, 2H, H-1''), 3.92 (s, 6H, 3'''-, 5'''-OCH₃), 3.90 (s, 3H, 4'''-OCH₃), 2.73–2.66 (m, 2H, H-1'), 1.63–1.53 (m, 2H, H-2'), 0.94 (t, J = 7.7 Hz, 3H, H-3') ppm; ¹³C NMR (DMSO, 100.63 MHz) δ: 192.4 (C=O), 172.8 (C-2''), 163.7 (C-2), 162.5 (C-4), 153.7 (C-3''', -5'''), 145.0 (C-β), 140.8 (C-4'''), 130.1 (C-5), 130.4 (C-1'''), 129.0 (C-6), 119.7 (C-α), 119.4 (C-3), 115.3 (C-1), 106.1 (C-2''', -6'''), 65.1 (C-1''), 61.2 (4'''-OCH₃), 56.4 (3'''-, 5'''-OCH₃), 24.7 (C-1'), 22.0 (C-2'), 14.4 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₂₃H₂₆O₁₀ (M+H⁺) 431.17004, found 431.16961.

Synthesis of (E)-2,2'-((2-Propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,3-phenylene)bis(oxy))diacetic Acid (12)

To a solution of methyl 2-(4-acetyl-3-hydroxy-2-propylphenoxy)acetate (10, 200 mg, 1 Eq, 751 μmol) in methanol was added an aqueous solution of 40% sodium hydroxide to pH 13–14. Then, a solution of 3,4,5-trimethoxybenzaldehyde (442 mg, 3 Eq, 2.25 mmol) in methanol was slowly added to the reaction mixture. The reaction was refluxed for 4 days. After cooling, the reaction was poured onto crushed ice and the pH was adjusted to 6–8, with a 5 M HCl solution. The obtained solid was filtrated, washed with water, dried, and purified via flash CC (SiO₂; chloroform:methanol, 9:1). A yellow solid (35% yield) corresponding to (E)-2,2'-((2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,3-phenylene)bis(oxy))diacetic acid (12) was obtained.

(E)-2,2'-((2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,3-phenylene)bis(oxy)) diacetic acid (12): 98.7% purity; mp 212–214 °C (chloroform); ¹H NMR (DMSO, 400.13 MHz) δ: 7.55–7.52 (m, 3H, H-α, -β, -6), 7.10 (s, 2H, H-2''', -6'''), 6.79 (d, J = 8.8 Hz, 1H, H-5), 4.80 (s, 2H, H-1''), 4.35 (s, 2H, H-1'''), 3.84 (s, 6H, 3'''-, 5'''-OCH₃), 3.70 (s, 3H, 4'''-OCH₃), 2.69 (t, J = 7.4 Hz, 1H, H-1'), 1.60–1.51 (m, 2H, H-2'), 0.93 (t, J = 7.4 Hz, 3H, H-3') ppm; ¹³C NMR (DMSO, 100.63 MHz) δ: 190.3 (C=O), 170.0 (C-2''), 169.5 (C-2'''), 159.6 (C-4), 156.3 (C-2), 153.1 (C-3''', -5'''), 144.0 (C-β), 139.6 (C-4'''), 130.1 (C-1'''), 129.0 (C-6), 125.4 (C-α), 125.1 (C-1), 124.5 (C-3), 107.4 (C-5), 106.2 (C-2''', -6'''), 71.4 (C-1'''), 65.0 (C-1'), 60.1 (4'''-OCH₃), 56.0 (3'''-, 5'''-OCH₃), 25.4 (C-1'), 22.3 (C-2'), 14.3 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₂₅H₂₈O₁₀ (M+Na⁺) 511.15747, found 511.15885.

Synthesis of (E)-2-(3-Hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)-N-(3,4,5-trimethoxyphenyl)acetamide (13)

(E)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic acid (11, 85 mg, 1 Eq, 0.20 mmol) was dissolved in 5 mL of anhydrous dichloromethane and N-ethyl-N-isopropylpropan-2-amine (51 mg, 69 μL, 2 Eq, 0.39 mmol) was added. Then, 3,4,5-trimethoxyaniline (43 mg, 1.2 Eq, 0.24 mmol) was added to the mixture. After 10 min, COMU (0.13 g, 1.5 Eq, 0.30 mmol) was also added to the mixture. The reaction proceeded for 3 h at room temperature with stirring. After completion, the reaction mixture was poured onto ice. The solution was subsequently washed with a 1 M HCl solution and a saturated NaHCO₃ solution, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the obtained reaction mixture was purified via TLC (SiO₂; dichloromethane:methanol; 97:3). A yellow solid (30% yield) corresponding to (E)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)-N-(3,4,5-trimethoxyphenyl)acetamide (13) was obtained.

(E)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)-N-(3,4,5-trimethoxyphenyl)acetamide (13): 95.9% purity; mp 199–201 °C (chloroform); ¹H NMR (DMSO, 400.13 MHz) δ: 13.66 (s, 1H, 2-OH), 10.18 (s, 1H, 3''-NH-), 8.27 (d, J = 9.2 Hz, 1H, H-6), 7.95 (d, J = 15.4 Hz, 1H, H-β), 7.80 (d, J = 15.3 Hz, 1H, H-α), 7.25 (s, 2H, H-2''', -6'''), 7.01 (s, 2H, H-5'', -9''), 6.61 (d, J = 9.2 Hz, 1H, H-5), 4.90 (s, 2H, H-1''), 3.86 (s, 6H, 3'''-, 5'''-OCH₃), 3.74 (s, 6H, 6''-, 8''-OCH₃), 3.72 (s, 3H, 4'''-OCH₃), 3.62 (s, 3H, 7'''-OCH₃),

2.66 (t, $J = 7.6$ Hz, 1H, H-1'), 1.58–1.51 (m, 2H, H-2'), 0.94 (t, $J = 7.4$ Hz, 3H, H-3'') ppm; ^{13}C NMR (DMSO, 100.63 MHz) δ : 192.4 (C=O), 165.8 (C-2''), 162.6 (C-2), 162.1 (C-4), 153.1 (C-3''', -5'''), 152.8 (C-6'', -8''), 145.0 (C- β), 140.0 (C-4'''), 134.6 (C-4''), 133.7 (C-7''), 130.5 (C-6), 130.5 (C-1'''), 120.2 (C- α), 117.4 (C-3), 114.2 (C-1), 106.8 (C-2''', -6'''), 103.4 (C-5), 97.0 (C-5'', -9''), 67.2 (C-1''), 60.1 (4''-, 4'''-OCH₃), 56.2 (3'''-, 5'''-OCH₃), 55.7 (6''-, 8''-OCH₃), 24.2 (C-1'), 21.4 (C-2'), 14.2 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₃₂H₃₇NO₁₀ (M+Na⁺) 618.23097, found 618.23023.

3.1.3. Synthesis of Compound 7 Analogues with a Flavone Scaffold (15, 16, and 18)

Synthesis of *tert*-Butyl (2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)carbamate (14)

To a solution of *tert*-butyl (*E*)-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)carbamate (6, 190 mg, 1 Eq, 369 μmol) in DMSO (10 mL/mmole of chalcone), I₂ (935 μg , 0.01 Eq, 3.69 μmol) was added. The mixture was heated at reflux for 24 h. Then, the mixture was poured into ice and a sodium thiosulfate solution (10%) was added. The obtained mixture was extracted with ethyl acetate, washed with water, and then dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the obtained reaction mixture was purified via TLC (SiO₂, chloroform:methanol; 95:5). A white solid (30% yield) corresponding to *tert*-butyl (2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)carbamate (14) was obtained.

***tert*-butyl (2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)carbamate (14)**: 98.9% purity; mp 191–193 °C (ethyl acetate); ^1H NMR (DMSO, 400.14 MHz) δ : 7.88 (d, $J = 8.9$ Hz, 1H, H-5), 7.34 (s, 2H, H-2''', -6'''), 7.20 (d, $J = 8.9$ Hz, 1H, H-6), 7.07 (s, 1H, H-3), 7.02 (t, $J = 5.8$ Hz, 1H, 3''-NH-), 4.18 (t, $J = 5.5$ Hz, 2H, H-1''), 3.91 (s, 6H, 3'''-, 5'''-OCH₃), 3.90–3.67 (m, 2H, H-2''), 3.76 (s, 3H, 4'''-OCH₃), 2.74 (t, $J = 7.1$ Hz, 2H, H-1'), 1.68–1.61 (m, 2H, H-2'), 1.38 (s, 9H, H-6''), 0.97 (t, $J = 7.3$ Hz, 3H, H-3') ppm; ^{13}C NMR (DMSO, 100.63 MHz) δ : 177.0 (C=O), 161.8 (C-2), 160.6 (C-7), 155.7 (C-4''), 154.4 (C-8a), 153.3 (C-3''', -5'''), 140.4 (C-4'''), 126.8 (C-1'''), 123.8 (C-5), 118.2 (C-4a), 117.2 (C-8), 110.4 (C-6), 106.1 (C-3), 103.5 (C-2''', -6'''), 77.7 (C-5''), 67.6 (C-1''), 60.2 (4'''-OCH₃), 56.3 (C-2''), 56.1 (3'''-, 5'''-OCH₃), 28.2 (6''-CH₃), 24.8 (C-1'), 22.1 (C-2'), 14.2 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₂₈H₃₅NO₈ (M+H⁺) 514.24354, found 514.24311.

Synthesis of (*E*)-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (15)

To a solution of (*E*)-*N*-(2-(3-hydroxy-2-propyl-4-((*E*)-3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (7, 10 mg, 1 Eq, 16 μmol) in DMSO (10 mL/mmole of chalcone), I₂ (40 μg , 0.01 Eq, 0.16 μmol) was added. The mixture was heated at reflux for 2 h. Then, the mixture was poured into ice and a sodium thiosulfate solution (10%) was added. The obtained mixture was extracted with ethyl acetate, washed with water, and then dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the obtained reaction mixture was purified via TLC (SiO₂, chloroform:methanol; 95:5). A white solid (35% yield) corresponding to (*E*)-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (15) was obtained.

(*E*)-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (15): 98.4% purity; mp 198–199 °C (chloroform); ^1H NMR (CDCl₃, 400.13 MHz) δ : 8.09 (d, $J = 8.9$ Hz, 1H, H-5), 7.59 (d, $J = 15.8$ Hz, 1H, H- β), 7.15 (s, 2H, H-2''', -6'''), 7.02 (d, $J = 8.9$ Hz, 1H, H-6), 6.73 (s, 2H, H-6'', -10''), 6.72 (s, 1H, H-3), 6.32 (d, $J = 15.5$ Hz, 1H, H- α), 5.97 (t, $J = 5.7$ Hz, 1H, 3''-NH-), 4.28 (t, $J = 5.2$ Hz, 2H, H-1''), 3.95 (s, 6H, 3'''-, 5'''-OCH₃), 3.94 (s, 3H, 4'''-OCH₃), 3.88 (s, 6H, 7''-, 9''-OCH₃), 3.87 (s, 3H, 8''-OCH₃), 3.95–3.90 (m, 2H, H-2''), 2.98 (t, $J = 7.5$ Hz, 1H, H-1'), 1.78–1.72 (m, 2H, H-2'), 1.06 (t, $J = 7.4$ Hz, 3H, H-3') ppm; ^{13}C NMR (CDCl₃, 100.63 MHz) δ : 178.9 (C=O), 166.2 (C-4''), 162.9 (C-2), 160.6 (C-7), 155.4 (C-8a), 153.8 (C-3''', -5'''), 153.6 (C-7'', -9''), 142.1 (C- β), 140.0 (C-4'''), 139.2 (C-8''), 130.4 (C-5''), 127.4 (C-1'''), 124.7 (C-5), 119.4 (C-4a), 119.3

(C- α), 118.7 (C-8), 109.9 (C-6), 106.6 (C-3), 105.2 (C-2''', -6'''), 103.5 (C-6'', -10''), 67.8 (C-1''), 61.2 (4'''-OCH₃), 61.1 (4''-OCH₃), 56.4 (3'''-, 5'''-OCH₃), 56.3 (7''-, 9''-OCH₃), 39.5 (C-2''), 25.7 (C-1'), 22.8 (C-2'), 14.7 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₃₅H₃₉NO₁₀ (M+CH₃OHH⁺) 666.29089, found 666.29022.

Synthesis of 3,4,5-Trimethoxy-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)benzamide (16)

To a solution of (*E*)-*N*-(2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-3,4,5-trimethoxybenzamide (8, 10 mg, 1 Eq, 16 μ mol) in DMSO (10 mL/mmol of chalcone), I₂ (42 μ g, 0.01 Eq, 0.16 μ mol) was added. The mixture was heated at reflux for 2 h. Then, the mixture was poured into ice and a sodium thiosulfate solution (10%) was added. The obtained mixture was extracted with ethyl acetate, washed with water, and then dried over anhydrous sodium sulfate. The solvent was evaporated to dryness and the reaction mixture was purified via TLC (SiO₂, chloroform:methanol; 95:5). A white solid (33% yield) corresponding to 3,4,5-trimethoxy-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)benzamide (16) was obtained.

3,4,5-trimethoxy-*N*-(2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)ethyl)benzamide (16): 95.8% purity; mp 196–199 °C (chloroform); ¹H NMR (DMSO, 400.13 MHz) δ : 8.64 (t, *J* = 5.6 Hz, 1H, 3''-NH-), 7.90 (d, *J* = 8.8 Hz, 1H, H-5), 7.33 (s, 2H, H-2''', -6'''), 7.27 (d, *J* = 8.9 Hz, 1H, H-6), 7.07 (s, 2H, H-6'', -10''), 7.07 (s, 1H, H-3), 4.02 (t, *J* = 5.2 Hz, 2H, H-1''), 3.90 (s, 6H, 3'''-, 5'''-OCH₃), 3.81 (s, 6H, 7''-, 9''-OCH₃), 3.75 (s, 3H, 4'''-OCH₃), 3.69 (s, 3H, 8''-OCH₃), 3.51–3.46 (m, 2H, H-2''), 2.89 (t, *J* = 7.4 Hz, 2H, H-1'), 1.68–1.59 (m, 2H, H-2'), 0.89 (t, *J* = 7.4 Hz, 3H, H-3') ppm; ¹³C NMR (DMSO, 100.63 MHz) δ : 177.4 (C=O), 166.1 (C-4''), 162.5 (C-2), 160.2 (C-7), 155.9 (C-8a), 154.5 (C-3''', -5'''), 154.4 (C-7'', -9''), 140.4 (C-4'''), 140.2 (C-8''), 129.8 (C-5''), 126.8 (C-1'''), 124.3 (C-5), 119.8 (C-4a), 117.3 (C-8), 109.7 (C-6), 106.0 (C-3), 104.7 (C-6'', -10''), 103.5 (C-2''', -6'''), 67.6 (C-1''), 61.4 (4'''-OCH₃), 60.0 (8''-OCH₃), 56.1 (3'''-, 5'''-OCH₃), 55.9 (7''-, 9''-OCH₃), 38.9 (C-2''), 30.7 (C-1'), 22.1 (C-2'), 14.1 (C-3') ppm; HRMS (ESI⁺): m/z Anal. Calc. for C₃₃H₃₇NO₁₀ (M+H⁺) 608.24902, found 608.24725.

Synthesis of 2-((4-oxo-8-Propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)-*N*-(3,4,5-trimethoxyphenyl)acetamide (17)

Method A: To a solution of (*E*)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)-*N*-(3,4,5-trimethoxyphenyl)acetamide (13, 100 mg, 1 Eq, 168 μ mol) in DMSO (10 mL/mmol of chalcone), I₂ (427 μ g, 0.01 Eq, 1.68 μ mol) was added. The mixture was heated at reflux for 24 h. Then, the mixture was poured into ice and a sodium thiosulfate solution (10%) was added. The obtained mixture was extracted with ethyl acetate, washed with water, and then dried over anhydrous sodium sulfate. The solvent was evaporated to dryness and the obtained mixture was purified via TLC (SiO₂; chloroform:methanol; 95:5). A yellow solid (30% yield) corresponding to 2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)-*N*-(3,4,5-trimethoxyphenyl)acetamide (17) was obtained.

Method B: 2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)acetic acid (18, 100 mg, 1 Eq, 233 μ mol) was dissolved in 5 mL of anhydrous dichloromethane and *N*-ethyl-*N*-isopropylpropan-2-amine (60.3 mg, 81.3 μ L, 2 Eq, 467 μ mol), and 3,4,5-trimethoxyaniline (51.3 mg, 1.2 Eq, 280 μ mol) was added to the mixture. After 10 min, COMU (150 mg, 1.5 Eq, 350 μ mol) was also added to the mixture. The reaction proceeded for 5 h at room temperature with stirring. After completion, the reaction mixture was poured onto ice. The solution was subsequently washed with 1M HCl solution and saturated NaHCO₃ solution, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness and the obtained reaction mixture was purified via TLC (SiO₂; chloroform:methanol; 95:5). A yellow solid (17.5% yield) corresponding to 2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4*H*-chromen-7-yl)oxy)-*N*-(3,4,5-trimethoxyphenyl)acetamide (17) was obtained.

2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4H-chromen-7-yl)oxy)-N-(3,4,5-trimethoxyphenyl)acetamide (17): 96.4% purity; **mp** 195–197 °C (chloroform); **¹H NMR** (DMSO, 400.13 MHz) δ : 10.15 (s, 1H, 3''-NH-), 7.90 (d, J = 9.1 Hz, 1H, H-5), 7.36 (s, 2H, H-2''', -6'''), 7.00 (s, 2H, H-5'', -9''), 7.14 (d, J = 9.0 Hz, 1H, H-6), 7.10 (s, 1H, H-3), 4.94 (s, 2H, H-1''), 3.92 (s, 6H, 3'''-, 5'''-OCH₃), 3.76 (s, 3H, 4'''-OCH₃), 3.76 (s, 6H, 6''-, 8''-OCH₃), 3.62 (s, 3H, 7''-OCH₃), 3.07 (t, J = 7.3 Hz, 1H, H-1'), 1.71–1.67 (m, 2H, H-2'), 1.01 (t, J = 7.3 Hz, 3H, H-3') ppm; **¹³C NMR** (DMSO, 100.63 MHz) δ : 177.0 (C=O), 166.9 (C-2''), 162.9 (C-2), 160.1 (C-7), 154.6 (C-8a), 153.0 (C-3''', -5'''), 152.8 (C-6'', -8''), 140.0 (C-4'''), 134.6 (C-7''), 133.8 (C-4''), 126.7 (C-1'''), 123.7 (C-5), 119.5 (C-8), 118.5 (C-4a), 110.4 (C-6), 106.1 (C-3), 103.8 (C-2''', -6'''), 97.0 (C-5'', -9''), 67.9 (C-1''), 60.3 (4'''-OCH₃), 60.1 (7''-OCH₃), 56.1 (3'''-, 5'''-OCH₃), 55.7 (6''-, 8''-OCH₃), 24.1 (C-1'), 22.3 (C-2'), 14.5 (C-3') ppm; **HRMS** (ESI⁺): m/z Anal. Calc. for C₃₃H₃₅NO₁₀ (M+K⁺) 632.18925, found 632.18769.

2-((4-oxo-8-Propyl-2-(3,4,5-trimethoxyphenyl)-4H-chromen-7-yl)oxy)acetic Acid (18)

To a solution of (*E*)-2-(3-hydroxy-2-propyl-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)acetic acid (**11**, 100 mg, 1 Eq, 232 μ mol) in DMSO (10mL/mmol of chalcone), I₂ (590 μ g, 0.01 Eq, 2.32 μ mol) was added. The mixture was heated at reflux for 24 h. Then, the mixture was poured into ice and a sodium thiosulfate solution (10%) was added. The obtained mixture was extracted with ethyl acetate, washed with water, and then dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the obtained oil was purified via TLC (SiO₂, n-hexane: ethyl acetate:formic acid (3:7:0.1%). A white solid (35% yield) corresponding to 2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4H-chromen-7-yl)oxy)acetic acid (**18**) was obtained.

2-((4-oxo-8-propyl-2-(3,4,5-trimethoxyphenyl)-4H-chromen-7-yl)oxy)acetic acid (18): 95.9% purity; **mp** 199–201 °C (chloroform); **¹H NMR** (THF, 400.13 MHz) δ : 7.92 (d, J = 8.8 Hz, 1H, H-5), 7.38 (s, 2H, H-2''', -6'''), 7.10 (d, J = 8.9 Hz, 1H, H-6), 7.01 (s, 1H, H-3), 4.85 (s, 2H, H-1''), 3.94 (s, 6H, 3'''-, 5'''-OCH₃), 3.79 (s, 3H, 4'''-OCH₃), 3.04 (t, J = 7.7 Hz, 2H, H-1'), 1.73–1.72 (m, 2H, H-2'), 1.04 (t, J = 7.4 Hz, 3H, H-3') ppm; **¹³C NMR** (THF, 100.63 MHz) δ : 178.1 (C=O), 170.8 (C-2''), 163.2 (C-2), 161.1 (C-7), 156.1 (C-8a), 154.9 (C-3''', -5'''), 142.2 (C-4'''), 128.3 (C-1'''), 124.9 (C-5), 119.8 (C-8), 119.2 (C-4a), 111.1 (C-6), 107.3 (C-3), 104.7 (C-2''', -6'''), 66.4 (C-1''), 61.0 (4'''-OCH₃), 57.0 (3'''-, 5'''-OCH₃), 26.4 (C-1'), 23.5 (C-2'), 15.1 (C-3') ppm; **HRMS** (ESI⁺): m/z Anal. Calc. for C₂₃H₂₄O₈ (M+H⁺) 429.15439, found 429.15658.

3.2. Biological Activity

3.2.1. Cell Culture

A375-C5 (melanoma) and MCF-7 (breast adenocarcinoma) cell lines were obtained from the European Collection of Cell Culture, UK, and were grown in RPMI-1640 medium (Roswell Park Memorial Institute, Biochrom, Cambridge, UK) with 5% inactivated FBS (fetal bovine serum, Biochrom). HCT-116 (colon adenocarcinoma) cells were grown in DMEM medium (Dulbecco's Modified Eagle's, Biochrom) with 5% inactivated FBS. The non-tumor human pulmonary alveolar epithelial cells (HPAEpiC) were obtained from ScienCell Research Laboratories and grown in DMEM medium supplemented with 10% FBS and 1% non-essential amino acids (Sigma-Aldrich Co., Saint Louis, MO, USA). All cell lines were maintained in a humidified incubator (Hera Cell, Heraeus, Hanau, Germany) at 37 °C and with 5% CO₂, and cell viability was regularly monitored using the exclusion trypan blue dye.

3.2.2. Compounds

All tested compounds were dissolved to 60 μ M in sterile DMSO (Sigma-Aldrich Co., Ltd., Gillingham, UK). To preserve the activities of compounds, several aliquots were prepared and stored at –20 °C. Immediately prior to use, compounds were diluted in fresh culture medium at the required concentrations.

3.2.3. Sulforodamine B (SRB) Assay

A total of 5.0×10^4 A375-C5, MCF-7, and HCT-116 cells, or 6.0×10^4 HPAEpiC cells were seeded in 96-well plates and incubated at 37 °C and 5% CO₂ to allow for cell attachment. After 24 h, cells were treated with two-fold serial dilutions of test compounds (0–150 µM), or with DMSO as the compound solvent. In parallel, cells in a time-zero (T0) plate, without treatment, were fixed with 50% (*m/v*) trichloroacetic acid (TCA, Merck Millipore, Darmstadt, Germany), for 1 h at 4 °C, and then washed with distilled water and left to dry. Forty-eight hours after compound treatment, cells were fixed with 50% TCA and stained with SRB (Sigma-Aldrich Co., Ltd., Gillingham, UK) for 30 min at room temperature, followed by 5 rounds of washing with 1% (*v/v*) acetic acid (Merck Milli-pore, Darmstadt, Germany). SRB–protein complexes were then solubilized with 10 µM Tris buffer (Sigma-Aldrich Co., Ltd., Gillingham, UK) for 30 min, and the absorbance was measured at 515 nm in a microplate reader (Biotek Synergy 2, BioTek Instruments, Inc., Winooski, VT, USA). A dose-response curve was obtained for each cell line, and the concentration that caused 50% cell growth inhibition (GI₅₀) was calculated.

3.2.4. Yeast Targeted Screening Assay

Saccharomyces cerevisiae (strain CG379) expressing human *wt* p53 alone and combined with human MDM2 were obtained in previous works [32,33]. For the expression of human proteins (routinely grown in minimal selective medium), cells were diluted to 0.05 OD600 in selective induction medium containing 2% (*w/w*) galactose, 1% (*w/w*) raffinose, 0.7% (*w/w*) yeast nitrogen base without amino acids from Difco (Quilaban, Sintra, Portugal), and all the amino acids required for yeast growth (50 g/mL) except leucine and tryptophan. Yeast cells were incubated at 30 °C under continuous orbital shaking (200 rpm) with 10 µM compounds or 0.1% DMSO only, for approximately 42 h (time required by the control yeast, co-transformed with the empty vectors and incubated with DMSO only, to achieve 0.4 OD600). Yeast growth was analyzed by counting the number of colony-forming units (CFU) after 2 days of incubation at 30 °C on Sabouraud Dextrose Agar from Liofilchem (Frilabo, Porto, Portugal).

3.2.5. Apoptosis Detection via Flow Cytometry

To evaluate apoptotic cell death, the “Annexin V-FITC Apoptosis Detection Kit” (eBioscience, Vienna, Austria) was used according to the manufacturer’s instructions. Briefly, 1.2×10^5 cells/well were seeded into 6-well plates, and 24 h later, cells were treated with compounds 6, 7, and 13. After 48 h, floating and adherent cells were collected, pelleted via centrifugation (1000 rpm, 5 min), and suspended in binding buffer. Annexin V-FITC was added and incubated for 10 min, protected from light. Cells were washed and resuspended in binding buffer, and 20 µg/mL of propidium iodide (PI) was added. Fluorescence was assessed using the BD Accuri™ C6 Plus flow cytometer (BD Biosciences, Qume Drive, San Jose, CA, USA), and the data were analyzed with the BD Accuri™ C6 Plus software (version 1.0.27.1, San Jose, CA, USA). At least 20,000 events per sample were collected.

3.2.6. DAPI Staining

A total of 1.2×10^5 cells were grown on poly-L-lysine-coated coverslips for 24 h. Then, cells were treated with 6, 7, and 13, and fixed with methanol (Sigma-Aldrich, Co., Ltd., Gillingham, UK) for 10 min at –20 °C and washed 3 times with PBS for 5 min. DNA was stained with 2 µg/mL 40,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) diluted in Vectashield mounting medium (Vector, H-1000, Burlingame, CA, USA).

3.2.7. Mitotic Index Determination

A total of 1.2×10^5 HCT-116 cells were grown in six-well dishes and treated for 24 h with 3.26 µM of compound 7. Cells treated with 1 µM nocodazole were used as a positive control for antimetabolic activity. Untreated cells and cells treated with DMSO were included to exclude the cytotoxicity of the compound solvent. Mitotic index, and the percentage

of mitotic cells over the total cell population were determined via cell-rounding under phase-contrast microscopy from at least ten random microscope fields.

3.2.8. Immunofluorescence

Cells were treated as for DAPI staining. After methanol fixation, cells were blocked with 10% FBS in PBST (0.05% Tween-20 in PBS) for 30 min at room temperature, followed by 1 h incubation with a primary antibody (mouse anti- α -tubulin, 1:2500, Sigma-Aldrich Co., Ltd., Gillingham, UK) diluted in 5% FBS in PBST. Then, cells were washed three times in PBST and incubated with an Alexa Fluor 488 conjugated secondary antibody (1:1500, Molecular Probes, Eugene, OR, USA). DNA was stained with DAPI.

3.2.9. Image Acquisition and Processing

For phase contrast microscopy images, a Nikon TE 2000-U microscope (Nikon, Amsterdam, The Netherlands) with a 10 \times objective was used, coupled to a DXM1200F digital camera with Nikon ACT-1 software (Melville, NY, USA). For fluorescence images, an Axio Observer Z.1 SD microscope (Carl Zeiss, Germany) was used, coupled to an AxioCam MR3, with the Plan Aplanachromat 63 \times /NA 1.4 objective. The images were processed using ImageJ, version 1.51.

3.2.10. Statistical Analysis

All assays were performed in triplicate with at least three independent experiments. Data were expressed as mean \pm standard deviation (SD), statistical analysis was carried out in GraphPad Prism Software Inc. v6 using an unpaired t-test, and values of * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$ were considered as statistically significant.

3.3. In Silico Prediction of Drug-Likeness

The selected compounds were further investigated for drug-likeness properties, namely, molecular descriptors/physicochemical properties, by SwissADME (<http://www.swissadme.ch/>), (accessed on 12 May 2023).

4. Conclusions

Inspired by **CM-M345** (1) and **BP-M345** (2), a new series of chalcone-trimethoxycinnamide/trimethoxyphenylamide hybrids have been designed, synthesized, and evaluated for their antitumor activity against melanoma (A375-C5), breast adenocarcinoma (MCF-7), and colorectal carcinoma (HCT116) cell lines, as well as non-tumor HPAEpiC cells. Among these, compounds **6**, **7**, and **13** demonstrated potent antiproliferative activity in the studied human tumor cell lines, with this effect being particularly intensified against colorectal tumor cells, with a relevant degree of selectivity when compared to non-tumor cells for compound **7**. The three referred compounds exert antitumor activity against colorectal tumor cells through apoptosis. Mechanistically, compound **7** emerged as an antimetabolic agent that, through its antimicrotubule activity, induces mitotic delay in colorectal tumor cells, and consequently, cell death. Notably, compound **7** affected colorectal tumor cells more severely than the non-tumor cells, indicating a high degree of selectivity, as suggested by the 17-fold higher GI₅₀ value of the compound on non-tumor cells. This highlights the potential of **7** as a hit compound, since the discovery of compounds with selective cytotoxicities that are capable of distinguishing between normal and tumor cells is a major challenge in tumor therapy. Considering the results obtained through in silico drug-likeness prediction, in the near future, the optimization of this compound should also consider the improvement of its drug-likeness profile, namely through nanotechnology.

Supplementary Materials: The following are available online <https://www.mdpi.com/article/10.3390/ph16060879/s1>. **Figure S1.** ¹H and ¹³C NMR of compound **3**, **Figure S2.** ¹H and ¹³C NMR of compound **4**, **Figure S3.** ¹H and ¹³C NMR of compound **5**, **Figure S4.** ¹H and ¹³C NMR of compound **6**, **Figure S5.** ¹H and ¹³C NMR of compound **7**, **Figure S6.** ¹H and ¹³C NMR of compound

8, **Figure S7**. ^1H and ^{13}C NMR of compound 9, **Figure S8**. ^1H and ^{13}C NMR of compound 10, **Figure S9**. ^1H and ^{13}C NMR of compound 11, **Figure S10**. ^1H and ^{13}C NMR of compound 12, **Figure S11**. ^1H and ^{13}C NMR of compound 13, **Figure S12**. ^1H and ^{13}C NMR of compound 14, **Figure S13**. ^1H and ^{13}C NMR of compound 15, **Figure S14**. ^1H and ^{13}C NMR of compound 16, **Figure S15**. ^1H and ^{13}C NMR of compound 17, **Figure S16**. ^1H and ^{13}C NMR of compound 18, **Figure S17**. ^1H and ^{13}C NMR of compound 19, **Figure S18**. ^1H and ^{13}C NMR of compound 20, **Figure S17**. HRMS of compound 5, **Figure S18**. HRMS of compound 6, **Figure S19**. HRMS of compound 7, **Figure S20**. HRMS of compound 8, **Figure S21**. HRMS of compound 10, **Figure S22**. HRMS of compound 11, **Figure S23**. HRMS of compound 12, **Figure S24**. HRMS of compound 13, **Figure S25**. HRMS of compound 14, **Figure S26**. HRMS of compound 15, **Figure S27**. HRMS of compound 16, **Figure S28**. HRMS of compound 17, **Figure S29**. HRMS of compound 18, **Figure S30**. Peak purity of compound 5, **Figure S31**. Peak purity of compound 6, **Figure S32**. Peak purity of compound 7, **Figure S33**. Peak purity of compound 8, **Figure S34**. Peak purity of compound 9, **Figure S35**. Peak purity of compound 10, **Figure S36**. Peak purity of compound 11, **Figure S37**. Peak purity of compound 12, **Figure S38**. Peak purity of compound 13, **Figure S39**. Peak purity of compound 14, **Figure S40**. Peak purity of compound 15, **Figure S41**. Peak purity of compound 16, **Figure S42**. Peak purity of compound 17, **Figure S43**. Peak purity of compound 18.

Author Contributions: Conceptualization, H.C.; methodology, J.M., P.M.A.S. and M.B.; software, J.M.; formal analysis, J.M., P.M.A.S., H.C. and H.B.; investigation, J.M., P.M.A.S. and M.B.; resources, H.C., H.B., M.P. and L.S.; writing—original draft preparation, J.M. and P.M.A.S.; writing—review and editing, H.C., H.B., M.P. and L.S.; supervision, H.C., H.B. and L.S.; project administration, M.P. and H.B.; funding acquisition, M.P. and H.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially supported by Strategic Funding UIDB/04423/2020 and UIDP/04423/2020 (Group of Marine Natural Products and Medicinal Chemistry, CIIMAR), and UIDB/50006/2020 (LAQV/REQUIMTE), through national funds provided by the FCT and ERDF, within the framework of the program PT2020, and by CESPU—Cooperativa de Ensino Superior Politécnico e Universitário, under the project Flav4Tumor-GI2-CESPU-2022. Joana Moreira acknowledges her grant (SFRH/BD/135852/2018).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Acknowledgments: The authors thank Sara Cravo and Gisela Adriano for all of the technical and scientific support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Moreira, J.; Saraiva, L.; Pinto, M.M.; Cidade, H. Bioactive Diarylpentanoids: Insights into the Biological Effects beyond Antitumor Activity and Structure-Activity Relationships. *Molecules* **2022**, *27*, 6340. [[CrossRef](#)] [[PubMed](#)]
2. Pereira, D.; Pinto, M.; Correia-da-Silva, M.; Cidade, H. Recent Advances in Bioactive Flavonoid Hybrids Linked by 1, 2, 3-Triazole Ring Obtained by Click Chemistry. *Molecules* **2021**, *27*, 230. [[CrossRef](#)] [[PubMed](#)]
3. Dhaliwal, J.S.; Moshawih, S.; Goh, K.W.; Loy, M.J.; Hossain, M.S.; Hermansyah, A.; Kotra, V.; Kifli, N.; Goh, H.P.; Dhaliwal, S.K.S. Pharmacotherapeutics applications and chemistry of chalcone derivatives. *Molecules* **2022**, *27*, 7062. [[CrossRef](#)] [[PubMed](#)]
4. Elkanzi, N.A.; Hrichi, H.; Alolayan, R.A.; Derafa, W.; Zahou, F.M.; Bakr, R.B. Synthesis of chalcones derivatives and their biological activities: A review. *ACS Omega* **2022**, *7*, 27769–27786. [[CrossRef](#)]
5. Salehi, B.; Quispe, C.; Chamkhi, I.; El Omari, N.; Balahbib, A.; Sharifi-Rad, J.; Bouyahya, A.; Akram, M.; Iqbal, M.; Docea, A.O. Pharmacological properties of chalcones: A review of preclinical including molecular mechanisms and clinical evidence. *Front. Pharmacol.* **2021**, *11*, 592654. [[CrossRef](#)]
6. Moreira, J.; Saraiva, L.; Pinto, M.M.; Cidade, H. Diarylpentanoids with antitumor activity: A critical review of structure-activity relationship studies. *Eur. J. Med. Chem.* **2020**, *192*, 112177. [[CrossRef](#)]
7. Moreira, J.; Almeida, J.; Saraiva, L.; Cidade, H.; Pinto, M. Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness. *Molecules* **2021**, *26*, 3737. [[CrossRef](#)]
8. Liu, W.; He, M.; Li, Y.; Peng, Z.; Wang, G. A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors. *J. Enzyme Inhib. Med. Chem.* **2022**, *37*, 9–38. [[CrossRef](#)]

9. Paulraj, F.; Abas, F.; H Lajis, N.; Othman, I.; Naidu, R. Molecular pathways modulated by curcumin analogue, diarylpentanoids in cancer. *Biomolecules* **2019**, *9*, 270. [[CrossRef](#)]
10. Brandão, P.; Loureiro, J.B.; Carvalho, S.; Hamadou, M.H.; Cravo, S.; Moreira, J.; Pereira, D.; Palmeira, A.; Pinto, M.; Saraiva, L.; et al. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity. *Eur. J. Med. Chem.* **2018**, *156*, 711–721. [[CrossRef](#)]
11. Pinto, P.; Machado, C.M.; Moreira, J.; Almeida, J.D.P.; Silva, P.M.; Henriques, A.C.; Soares, J.X.; Salvador, J.A.; Afonso, C.; Pinto, M.; et al. Chalcone derivatives targeting mitosis: Synthesis, evaluation of antitumor activity and lipophilicity. *Eur. J. Med. Chem.* **2019**, *184*, 111752. [[CrossRef](#)] [[PubMed](#)]
12. Moreira, J.; Almeida, J.; Loureiro, J.B.; Ramos, H.; Palmeira, A.; Pinto, M.M.; Saraiva, L.; Cidade, H. A Diarylpentanoid with Potential Activation of the p53 Pathway: Combination of in silico Screening Studies, Synthesis, and Biological Activity Evaluation. *ChemMedChem* **2021**, *16*, 2969–2981. [[CrossRef](#)] [[PubMed](#)]
13. Horta, B.; Freitas-Silva, J.; Silva, J.; Dias, F.; Teixeira, A.L.; Medeiros, R.; Cidade, H.; Pinto, M.; Cerqueira, F. Antitumor Effect of Chalcone Derivatives against Human Prostate (LNCaP and PC-3), Cervix HPV-Positive (HeLa) and Lymphocyte (Jurkat) Cell Lines and Their Effect on Macrophage Functions. *Molecules* **2023**, *28*, 2159. [[CrossRef](#)] [[PubMed](#)]
14. Mendanha, D.; Vieira de Castro, J.; Moreira, J.; Costa, B.M.; Cidade, H.; Pinto, M.; Ferreira, H.; Neves, N.M. A new chalcone derivative with promising antiproliferative and anti-invasion activities in glioblastoma cells. *Molecules* **2021**, *26*, 3383. [[CrossRef](#)] [[PubMed](#)]
15. Masawang, K.; Pedro, M.; Cidade, H.; Reis, R.M.; Neves, M.P.; Corrêa, A.G.; Sudprasert, W.; Bousbaa, H.; Pinto, M.M. Evaluation of 2', 4'-dihydroxy-3, 4, 5-trimethoxychalcone as antimitotic agent that induces mitotic catastrophe in MCF-7 breast cancer cells. *Toxicol. Lett.* **2014**, *229*, 393–401. [[CrossRef](#)]
16. Pereira, D.; Lima, R.T.; Palmeira, A.; Seca, H.; Soares, J.; Gomes, S.; Raimundo, L.; Maciel, C.; Pinto, M.; Sousa, E. Design and synthesis of new inhibitors of p53–MDM2 interaction with a chalcone scaffold. *Arab. J. Chem.* **2019**, *12*, 4150–4161. [[CrossRef](#)]
17. Novais, P.; Silva, P.; Moreira, J.; Palmeira, A.; Amorim, I.; Pinto, M.; Cidade, H.; Bousbaa, H. BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity. *Molecules* **2021**, *26*, 7139. [[CrossRef](#)]
18. Prota, A.E.; Danel, F.; Bachmann, F.; Bargsten, K.; Buey, R.M.; Pohlmann, J.; Reinelt, S.; Lane, H.; Steinmetz, M.O. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. *J. Mol. Biol.* **2014**, *426*, 1848–1860. [[CrossRef](#)]
19. Negi, A.S.; Gautam, Y.; Alam, S.; Chanda, D.; Luqman, S.; Sarkar, J.; Khan, F.; Konwar, R. Natural antitubulin agents: Importance of 3, 4, 5-trimethoxyphenyl fragment. *Bioorg. Med. Chem.* **2015**, *23*, 373–389. [[CrossRef](#)]
20. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular hybridization: A useful tool in the design of new drug prototypes. *Curr. Med. Chem.* **2007**, *14*, 1829–1852. [[CrossRef](#)]
21. Ebenezer, O.; Shapi, M.; Tuszyński, J.A. A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. *Int. J. Mol. Sci.* **2022**, *23*, 4001. [[CrossRef](#)] [[PubMed](#)]
22. Gaikwad, N.; Nanduri, S.; Madhavi, Y. Cinnamamide: An insight into the pharmacological advances and structure–Activity relationships. *Eur. J. Med. Chem.* **2019**, *181*, 111561. [[CrossRef](#)] [[PubMed](#)]
23. Marshall, W.S.; Goodson, T.; Cullinan, G.J.; Swanson-Bean, D.; Haisch, K.D.; Rinkema, L.E.; Fleisch, J.H. Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. *J. Med. Chem.* **1987**, *30*, 682–689. [[CrossRef](#)]
24. Da Nóbrega, F.R.; Ozdemir, O.; Nascimento Sousa, S.C.S.; Barboza, J.N.; Turkez, H.; De Sousa, D.P. Piplartine analogues and cytotoxic evaluation against glioblastoma. *Molecules* **2018**, *23*, 1382. [[CrossRef](#)]
25. Paier, C.R.K.; Maranhão, S.S.A.; Carneiro, T.R.; Lima, L.M.; Rocha, D.D.; Santos, R.D.S.; Farias, K.M.D.; Moraes-Filho, M.O.D.; Pessoa, C. Natural products as new antimitotic compounds for anticancer drug development. *Clinics* **2018**, *73*, e813s. [[CrossRef](#)] [[PubMed](#)]
26. Meanwell, N.A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. *Chem. Res. Toxicol.* **2011**, *24*, 1420–1456. [[CrossRef](#)]
27. Bade, R.; Chan, H.-F.; Reynisson, J. Characteristics of known drug space. Natural products, their derivatives and synthetic drugs. *Eur. J. Med. Chem.* **2010**, *45*, 5646–5652. [[CrossRef](#)]
28. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. *J. Pharmacol. Sci.* **1999**, *88*, 807–814. [[CrossRef](#)]
29. Maurya, A.; Singh, A.K.; Mishra, G.; Kumari, K.; Rai, A.; Sharma, B.; Kulkarni, G.T.; Awasthi, R. Strategic use of nanotechnology in drug targeting and its consequences on human health: A focused review. *Interv. Med. Appl. Sci.* **2019**, *11*, 38–54. [[CrossRef](#)]
30. Ezrahi, S.; Aserin, A.; Garti, N. Basic principles of drug delivery systems—The case of paclitaxel. *Adv. Colloid Interface Sci.* **2019**, *263*, 95–130. [[CrossRef](#)]
31. Zhang, L.; Zhang, N. How nanotechnology can enhance docetaxel therapy. *Int. J. Nanomed.* **2013**, *8*, 2927–2941. [[CrossRef](#)] [[PubMed](#)]

32. Leão, M.; Gomes, S.; Soares, J.; Bessa, C.; Maciel, C.; Ciribilli, Y.; Pereira, C.; Inga, A.; Saraiva, L. Novel simplified yeast-based assays of regulators of p53–MDMX interaction and p53 transcriptional activity. *FEBS J.* **2013**, *280*, 6498–6507. [[CrossRef](#)] [[PubMed](#)]
33. Leao, M.; Pereira, C.; Bisio, A.; Ciribilli, Y.; Paiva, A.M.; Machado, N.; Palmeira, A.; Fernandes, M.X.; Sousa, E.; Pinto, M. Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach. *Biochem. Pharmacol.* **2013**, *85*, 1234–1245. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.